arrow
J

J BOUSQUET

fraunhofer institute for translational medicine and pharmacology (itmp)
H指数:1
被引数:360

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Regional Patterns in the Prevalence of Patient‐Reported Urticaria Aggravating Factors: A Multinational Mobile Health Study

区域性患者报告荨麻疹加重因素患病率的模式:一项跨国移动健康研究

2026-11-080
OAAI
Natural Diversity of Grass Pollen in Europe—An EAACI Perspective

欧洲草花粉的自然多样性—<scp>EAACI</scp>观点

2026-10-080
PREAI
Use of Artificial Intelligence-Based Platforms to Support Searches in Evidence Synthesis Studies: A Study of the EAACI Methodology Committee

基于人工智能平台的证据综合研究检索支持应用:EAACI方法学委员会的研究

2026-09-130
OAAI
As-Needed Versus Regular Medication Use in the Treatment of Allergic Rhinitis in the Pollen Season: A MASK-air Study

花粉季节过敏性鼻炎治疗中按需用药与常规用药的比较:一项MASK-air研究

2026-09-100
OAAI
ARIA-EAACI 2025: Person-Centred, Digitally Enabled and Artificial Intelligence-Assisted Change Management in Airway Diseases

ARIA-EAACI 2025:气道疾病中以患者为中心、数字化赋能和人工智能辅助的变革管理

2026-09-030
OAAI
Distinction between allergic rhinitis alone and allergic rhinitis plus asthma in MASK-air ® real-world studies; a ARIA-WAO task force review

MASK-air ®真实世界研究中单纯过敏性鼻炎与过敏性鼻炎合并哮喘的区分;一项ARIA-WAO工作组综述

2026-07-010
OAAI
Allergic rhinitis in the elderly. In collaboration with ARIA guidelines

老年人过敏性鼻炎。与ARIA指南合作

2026-06-170
PRE
Estimating work-related indirect costs in allergic rhinitis and asthma using a daily combined symptom-medication score: a MASK-air® study in collaboration with the EAACI Methodology Committee

使用每日症状-药物联合评分估算过敏性鼻炎和哮喘的工作相关间接成本:EAACI方法学委员会协作的MASK-air®研究

2026-06-110
OAAI
Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK-air Study

过敏性鼻炎治疗方法在效用和生活质量方面的比较:一项MASK-air研究

2026-05-060
OAAI
Trace Elements in Allergy: Narrative Review

过敏中的微量元素:叙事性综述

2026-05-040
OAAI
Treatment Dose Increase Versus Co-Medication in Allergic Rhinitis: Systematic Review With Dose–Response Network Meta-Analysis

过敏性鼻炎的治疗剂量增加与联合用药比较:剂量-反应网络Meta分析的系统性综述

2026-05-010
OAAI
The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Utricaria, and Chronic Rhinosinusitis With Nasal Polyps

首个用于过敏领域的生物类似药:CT-P39(Omlyclo-Omalizumab-Igec)适用于哮喘、慢性自发性荨麻疹和伴有鼻息肉的慢性鼻窦炎

2026-04-250
PRE
Availability and Costs of Allergic Rhinitis Treatments Across the World: A Survey of ARIA Experts

全球过敏性鼻炎治疗的可及性与成本:ARIA专家调查

2026-04-180
OAAI
Obituary: Professor Dietrich Kraft (1937–2026)

讣告:迪特里希·克拉夫特教授(1937—2026)

2026-04-160
PRE
Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines—2024–2025 Revision: Part II—Guidelines on Oral and Ocular Treatments

变应性鼻炎及其对哮喘的影响(ARIA)-EAACI指南—2024–2025年修订版:第II部分—口服和眼部治疗指南

2026-03-240
OAAI
Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments

变应性鼻炎及其对哮喘的影响(ARIA)-EAACI指南—2024–2025年修订版:第一部分—关于鼻内治疗的指南

2025-12-010
OAAI
Evaluation of the Quality and Reliability of ChatGPT-4's Responses on Allergen Immunotherapy Using Validated Instruments for Health Information Quality Assessment

使用经过验证的健康信息质量评估工具,对ChatGPT-4在过敏原免疫治疗方面的回答质量和可靠性进行评估。

2025-11-290
OAAI